Related Experiment Videos
Pharmacokinetics of trimethoprim-sulfamethoxazole in children
Insights
This study evaluated trimethoprim-sulfamethoxazole (TMP-SMX) in children, finding it well-tolerated and effective for various infections. However, the dosage may be suboptimal for severe parenchymal infections.
Area of Science:
- Pediatric Pharmacology
- Infectious Diseases
- Antimicrobial Therapy
Background:
- Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely used antibiotic.
- Limited data exists on its efficacy and pharmacokinetics in young children.
- Optimizing pediatric dosing is crucial for effective treatment and preventing resistance.
Purpose of the Study:
- To assess the safety, tolerability, and efficacy of a specific TMP-SMX regimen in children aged 3 months to 10 years.
- To evaluate the pharmacokinetic profile, including serum concentrations and potential accumulation, of TMP-SMX in this pediatric population.
- To determine if the administered dosage is adequate for treating common childhood infections.
Main Methods:
- A cohort of 12 children aged 3 months to 10 years received TMP-SMX.
- The dosage administered was TMP (200 mg)--SMX (1000 mg)/m-2d in two equal doses.
- Serum concentrations of trimethoprim (TMP) were monitored over the first four days of treatment.
Main Results:
- The TMP-SMX regimen was easily administered, well-tolerated, and effective in most children.
- Steady-state serum concentrations of TMP were achieved by the third dose without significant accumulation.
- Preliminary data indicated slightly lower TMP levels in children under 3 years, with peak concentrations around 1.63 mug/ml on day 3.
Conclusions:
- The TMP-SMX regimen demonstrated good tolerability and efficacy for a range of infections in pediatric patients.
- While generally effective, the current dosage might be insufficient for treating severe parenchymal infections.
- Further investigation into dose optimization for specific pediatric infections is warranted.
Abstract:
The present report extends experience with the use of trimethoprim-sulfamethoxazole (TMP-SMX) in children aged 3 months to 10 years. The regimen was TMP (200 mg)--SMX (1000 mg)/m-2d given in two equal doses. The drug was easily administered, well tolerated and efficacious in the treatment of a variety of infections in 12 children. A steady state had been achieved by the third dose of medication and accumulation of either component during days 1 through 4 did not occur. Serum concentrations of TMP were slightly lower in children aged less than 3 years compared with those aged 3 to 6 years but the differences were small and these results are preliminary. Peak mean serum TMP concentration was highest at day 3 when it reached 1.63 mug/ml. It is concluded that this regimen may be suboptimal for some major parenchymal infections even though the therapeutic result was excellent in most children.